Wessex Asthma Cohort of Difficult Asthma

Asthma is now widely recognised to be a heterogeneous disease. The last two decades have seen the identification of a number of biological targets and development of various novel therapies. Despite this, asthma still represents a significant health and economic burden worldwide. Why some individuals should continue to suffer remains unclear. The Wessex Asthma Cohort of Difficult Asthma (WATCH) is an ongoing 'real-life', prospective study of patients in the University Hospital Southampton Foundation Trust (UHSFT) Difficult Asthma service. Research data capture is aligned with the extensive clinical characterisation required of a commissioned National Health Service (NHS) Specialist Centre for Severe Asthma. Data acquisition includes detailed clinical, health and disease-related questionnaires, anthropometry, allergy and lung function testing, radiological imaging (in a small subset) and collection of biological samples (blood, urine and sputum). Prospective data are captured in parallel to clinical follow up appointments, with data entered into a bespoke database. The pragmatic ongoing nature of the WATCH study allows comprehensive assessment of the real world clinical spectrum seen in a Specialist Asthma Centre and allows a longitudinal perspective of deeply phenotyped patients. It is anticipated that the WATCH cohort would act as a vehicle for potential collaborative asthma studies and will build upon our understanding of mechanisms underlying difficult asthma.

NCT Number	NCT03996590
Lead Sponsor	University Hospital Southampton NHS Foundation Trust Collaborators: Novartis, Boehringer Ingelheim, National Institutes of Health (NIH), Owlstone Ltd, National Institute for Health Research, United Kingdom
Conditions	Asthma
Enrollment	566 participants
Start Date	2015-04-22
Primary Completion	2050-12 (estimated)
Study Completion	2050-12 (estimated)
Updated on ClinicalTrials.gov	2024-01-19